Multiple Sclerosis

In Multiple Sclerosis, Hand Strength May Indicate Disease Status

In Multiple Sclerosis, Hand Strength May Indicate Disease Status

By

In patients with MS, hand function often correlates with measures of quality of life.

Multiple Sclerosis May Have Causal Link to Osteoporosis

Multiple Sclerosis May Have Causal Link to Osteoporosis

By

The prevalence of osteoporosis was greater in patients with MS than in matched controls.

In MS, Anxiety, Cognitive Fatigue May Affect Visual Memory

In MS, Anxiety, Cognitive Fatigue May Affect Visual Memory

By

Cognitive fatigue and anxiety are common symptoms reported by patients with multiple sclerosis.

Multiple Sclerosis Relapse Rate Linked to Puberty in Boys

Multiple Sclerosis Relapse Rate Linked to Puberty in Boys

By

Boys with onset of MS during puberty experienced an increased rate of relapse compared with boys with MS onset before or after puberty.

Vitamin D Deficiency Affects Cognition in Multiple Sclerosis

Vitamin D Deficiency Affects Cognition in Multiple Sclerosis

By

Longer studies are needed to further evaluate the effect of vitamin D supplementation on cognition in multiple sclerosis.

Pediatric Multiple Sclerosis Linked to Epstein-Barr, Herpes Simplex Virus Exposure

Pediatric Multiple Sclerosis Linked to Epstein-Barr, Herpes Simplex Virus Exposure

By

Increased risk of pediatric multiple sclerosis was observed in patients with prior exposure to EBV, HSV-1, and vitamin D deficiency.

In Relapsing MS, Fatigue, Limb Problems May Signal Risk for Disease Conversion

In Relapsing MS, Fatigue, Limb Problems May Signal Risk for Disease Conversion

By

In older patients with relapsing multiple sclerosis, patient-reported fatigue and problems with lower extremities may signal conversion to secondary progressive disease.

No Evidence of Disease Activity Achieved in Multiple Sclerosis with Dimethyl Fumarate

No Evidence of Disease Activity Achieved in Multiple Sclerosis with Dimethyl Fumarate

By

More participants achieved clinical NEDA with DMF than placebo over 2 years in the integrated analysis.

Ocrelizumab Approved for Progressive, Relapsing Multiple Sclerosis

Ocrelizumab Approved for Progressive, Relapsing Multiple Sclerosis

By

The biannual infusion is approved for the treatment of adults with relapsing and progressive forms of multiple sclerosis.

In Multiple Sclerosis, Anxiety May Signal Depression

In Multiple Sclerosis, Anxiety May Signal Depression

By

A study aimed to clarify the relationship between anxiety and depression in patients with multiple sclerosis.

RENEW Trial: Promising Results for Optic Neuritis Treatment

RENEW Trial: Promising Results for Optic Neuritis Treatment

By

Opicinumab may potentially enhance spontaneous remyelination after acute optic neuritis.

ICER Report: New Multiple Sclerosis Drugs More Effective, But Safety Concerns Abound

ICER Report: New Multiple Sclerosis Drugs More Effective, But Safety Concerns Abound

By

Several new multiple sclerosis drugs, including natalizumab, may be more effective at reducing relapses but still come with serious safety concerns.

Relapsing-Remitting Multiple Sclerosis Halted With Immunosuppression, Stem Cell Transplant

Relapsing-Remitting Multiple Sclerosis Halted With Immunosuppression, Stem Cell Transplant

By

Five years after treatment, nearly 70% of patients with relapsing-remitting multiple sclerosis showed no signs of disease progression.

MicroRNA in Multiple Sclerosis May Signify Disease Progression

MicroRNA in Multiple Sclerosis May Signify Disease Progression

By

Several microRNA were found to be associated with lesion volume and brain atrophy in multiple sclerosis.

Risk-Benefit Analysis Helps Determine Multiple Sclerosis Therapy

Risk-Benefit Analysis Helps Determine Multiple Sclerosis Therapy

By

Despite an elevated risk of PML, treatment with natalizumab results in slower disease progression than other treatments.

Epileptic Seizures in Multiple Sclerosis May Suggest Shared Pathology

Epileptic Seizures in Multiple Sclerosis May Suggest Shared Pathology

By

Patients with both MS and epileptic seizures had a younger age at onset of MS compared with those without seizures.

Case Report: Treatment With Alemtuzumab May Prompt Severe CNS Disease

Case Report: Treatment With Alemtuzumab May Prompt Severe CNS Disease

By

Researchers report 2 cases of a severe B-cell-mediated CNS disease after treatment with alemtuzumab in patients with multiple sclerosis.

Template Improves Quality of Report on MRI for Multiple Sclerosis

Template Improves Quality of Report on MRI for Multiple Sclerosis

By

More structured MRI reports may aid in the diagnosis of multiple sclerosis.

Potential Prognostic Biomarker for Clinically Isolated Syndrome

Potential Prognostic Biomarker for Clinically Isolated Syndrome

By

It is not clear whether CSF CD27 could provide novel or simply complementary prognostic value in clinically isolated syndrome.

Low Neonatal Vitamin D May Increase Risk of MS

Low Neonatal Vitamin D May Increase Risk of MS

By

Low levels of neonatal vitamin D may be linked with risk of developing multiple sclerosis.

Gray Matter, White Matter Ratio Predicts Multiple Sclerosis Progression

Gray Matter, White Matter Ratio Predicts Multiple Sclerosis Progression

By

Previous MRI studies focused on gray matter changes only.

Alemtuzumab May Reduce Disability in Early MS

Alemtuzumab May Reduce Disability in Early MS

By

The authors aimed to identify confirmed disability improvement (CDI), which reflects a clinically meaningful change in EDSS score.

Does Exercise Influence Risk of Multiple Sclerosis?

Does Exercise Influence Risk of Multiple Sclerosis?

By

Researchers still recommend that patients with MS engage in physical activity for cardiovascular benefits.

Experimental Multiple Sclerosis Drug May Prevent Disease in Mice

Experimental Multiple Sclerosis Drug May Prevent Disease in Mice

Researchers believe that the drug may help prevent MS, since there was a 96% reduction in harmful clusters of B cells.

Psychiatric Disorders Common in Pediatric MS, Demyelinating Diseases

Psychiatric Disorders Common in Pediatric MS, Demyelinating Diseases

By

Notably, patients who had documented psychotic and psychiatric disorders were more likely to be diagnosed with a demyelinating disease.

Dimethyl-Fumarate May Maintain NEDA After Natalizumab Discontinuation

Dimethyl-Fumarate May Maintain NEDA After Natalizumab Discontinuation

By

Over 90% of participants achieved NEDA-3 after being transitioned to dimethyl-fumarate from natalizumab.

Smoking May Accelerate White Matter Damage in Progressive MS

Smoking May Accelerate White Matter Damage in Progressive MS

By

The relationship between microstructural damage in NAWM and clinical measures was less clear, suggesting another mechanism.

Enriching Experiences May Protect Against Cognitive Decline in MS

Enriching Experiences May Protect Against Cognitive Decline in MS

By

Researchers examined whether the cognitive reserve hypothesis could predict cognitive decline, gray matter volume changes, and white matter volume changes in MS patients.

High-Fat Diets May Increase Relapse Risk in Pediatric MS

High-Fat Diets May Increase Relapse Risk in Pediatric MS

By

High-fat diets may increase the risk of relapse in children with MS, while high-vegetable diets may be protective.

Genetic Risk Score Identifies Pediatric Patients With Greater MS Relapse Risk

Genetic Risk Score Identifies Pediatric Patients With Greater MS Relapse Risk

By

Six polymorphisms were found to be strongly associated with vitamin D levels in the patient population.

Sign Up for Free e-newsletters